Bill > S07130

This bill amends the New York cannabis law to restrict the sale of cannabinoid hemp products by establishing a new requirement for the ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC). Specifically, the bill prohibits the sale of cannabinoid hemp products (except for flower and topical products) where the ratio of CBD to THC is less than 15:1. If CBD is not the primary marketed cannabinoid, the bill mandates that the sum of cannabinoids excluding THC must have a ratio of at least 15:1 to THC. This means that products with a higher proportion of THC relative to other cannabinoids would be prohibited from being sold. The legislation is designed to regulate the composition of hemp-derived products, likely to limit the psychoactive effects of THC while maintaining the potential therapeutic benefits of CBD and other cannabinoids. The bill would take effect immediately upon passage.

Government Affairs

https://www.nysenate.gov/legislation/bills/2025/S7130